Literature DB >> 3936300

Influenza virus antigens conjugated with a synthetic polyelectrolyte: a novel model of vaccines.

R V Petrov, R M Khaitov, V M Zhdanov, M S Sinyakov, A Sh Norimov, A V Nekrasov, I G Kharitonenkov, M V Shchipanova.   

Abstract

Haemagglutinin (HA), a mixture of haemagglutinin and neuraminidase (HA + NA), and matrix (M) protein were isolated from the influenza A virus and covalently coupled to a synthetic polyelectrolyte (P). A single injection into mice of the resultant conjugates (virogates) brought about efficient stimulation of the primary immune response specific to the corresponding viral antigens. Mice immunized with virogates HA.P or (HA + NA).P were largely protected against a lethal challenge infection with homologous virus. Immunization of mice with M.P virogate containing M protein originated from a 1934 influenza strain resulted in pronounced protection against a lethal challenge infection with a 1980 strain. Virogates are discussed as a novel model of artificial vaccines.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936300     DOI: 10.1016/0264-410x(85)90130-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

Review 1.  Polymer genomics: an insight into pharmacology and toxicology of nanomedicines.

Authors:  Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2006-10-06       Impact factor: 15.470

2.  Synthesis and characterization of antigenic influenza A M2e protein peptide-poly(acrylic) acid bioconjugate and determination of toxicity in vitro.

Authors:  Yasemin Budama Kilinc; Zeynep Mustafaeva Akdeste; Rabia Cakir Koc; Melahat Bagirova; Adil Allahverdiyev
Journal:  Bioengineered       Date:  2014-11-11       Impact factor: 3.269

3.  Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus.

Authors:  M K Ijaz; S K Attah-Poku; M J Redmond; M D Parker; M I Sabara; P Frenchick; L A Babiuk
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.